Cargando…

A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition

Telomere erosion in cells with insufficient levels of the telomerase reverse transcriptase (TERT), contributes to age‐associated tissue dysfunction and senescence, and p53 plays a crucial role in this response. We undertook a genome‐wide CRISPR screen to identify gene deletions that sensitized p53‐p...

Descripción completa

Detalles Bibliográficos
Autores principales: Benslimane, Yahya, Sánchez‐Osuna, María, Coulombe‐Huntington, Jasmin, Bertomeu, Thierry, Henry, Danielle, Huard, Caroline, Bonneil, Éric, Thibault, Pierre, Tyers, Mike, Harrington, Lea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045932/
https://www.ncbi.nlm.nih.gov/pubmed/33660365
http://dx.doi.org/10.1111/acel.13331
_version_ 1783678753863368704
author Benslimane, Yahya
Sánchez‐Osuna, María
Coulombe‐Huntington, Jasmin
Bertomeu, Thierry
Henry, Danielle
Huard, Caroline
Bonneil, Éric
Thibault, Pierre
Tyers, Mike
Harrington, Lea
author_facet Benslimane, Yahya
Sánchez‐Osuna, María
Coulombe‐Huntington, Jasmin
Bertomeu, Thierry
Henry, Danielle
Huard, Caroline
Bonneil, Éric
Thibault, Pierre
Tyers, Mike
Harrington, Lea
author_sort Benslimane, Yahya
collection PubMed
description Telomere erosion in cells with insufficient levels of the telomerase reverse transcriptase (TERT), contributes to age‐associated tissue dysfunction and senescence, and p53 plays a crucial role in this response. We undertook a genome‐wide CRISPR screen to identify gene deletions that sensitized p53‐positive human cells to telomerase inhibition. We uncovered a previously unannotated gene, C16ORF72, which we term Telomere Attrition and p53 Response 1 (TAPR1), that exhibited a synthetic‐sick relationship with TERT loss. A subsequent genome‐wide CRISPR screen in TAPR1‐disrupted cells reciprocally identified TERT as a sensitizing gene deletion. Cells lacking TAPR1 or TERT possessed elevated p53 levels and transcriptional signatures consistent with p53 upregulation. The elevated p53 response in TERT‐ or TAPR1‐deficient cells was exacerbated by treatment with the MDM2 inhibitor and p53 stabilizer nutlin‐3a and coincided with a further reduction in cell fitness. Importantly, the sensitivity to treatment with nutlin‐3a in TERT‐ or TAPR1‐deficient cells was rescued by loss of p53. These data suggest that TAPR1 buffers against the deleterious consequences of telomere erosion or DNA damage by constraining p53. These findings identify C16ORF72/TAPR1 as new regulator at the nexus of telomere integrity and p53 regulation.
format Online
Article
Text
id pubmed-8045932
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80459322021-04-16 A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition Benslimane, Yahya Sánchez‐Osuna, María Coulombe‐Huntington, Jasmin Bertomeu, Thierry Henry, Danielle Huard, Caroline Bonneil, Éric Thibault, Pierre Tyers, Mike Harrington, Lea Aging Cell Original Papers Telomere erosion in cells with insufficient levels of the telomerase reverse transcriptase (TERT), contributes to age‐associated tissue dysfunction and senescence, and p53 plays a crucial role in this response. We undertook a genome‐wide CRISPR screen to identify gene deletions that sensitized p53‐positive human cells to telomerase inhibition. We uncovered a previously unannotated gene, C16ORF72, which we term Telomere Attrition and p53 Response 1 (TAPR1), that exhibited a synthetic‐sick relationship with TERT loss. A subsequent genome‐wide CRISPR screen in TAPR1‐disrupted cells reciprocally identified TERT as a sensitizing gene deletion. Cells lacking TAPR1 or TERT possessed elevated p53 levels and transcriptional signatures consistent with p53 upregulation. The elevated p53 response in TERT‐ or TAPR1‐deficient cells was exacerbated by treatment with the MDM2 inhibitor and p53 stabilizer nutlin‐3a and coincided with a further reduction in cell fitness. Importantly, the sensitivity to treatment with nutlin‐3a in TERT‐ or TAPR1‐deficient cells was rescued by loss of p53. These data suggest that TAPR1 buffers against the deleterious consequences of telomere erosion or DNA damage by constraining p53. These findings identify C16ORF72/TAPR1 as new regulator at the nexus of telomere integrity and p53 regulation. John Wiley and Sons Inc. 2021-03-04 2021-04 /pmc/articles/PMC8045932/ /pubmed/33660365 http://dx.doi.org/10.1111/acel.13331 Text en © 2021 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Benslimane, Yahya
Sánchez‐Osuna, María
Coulombe‐Huntington, Jasmin
Bertomeu, Thierry
Henry, Danielle
Huard, Caroline
Bonneil, Éric
Thibault, Pierre
Tyers, Mike
Harrington, Lea
A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition
title A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition
title_full A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition
title_fullStr A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition
title_full_unstemmed A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition
title_short A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition
title_sort novel p53 regulator, c16orf72/tapr1, buffers against telomerase inhibition
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045932/
https://www.ncbi.nlm.nih.gov/pubmed/33660365
http://dx.doi.org/10.1111/acel.13331
work_keys_str_mv AT benslimaneyahya anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT sanchezosunamaria anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT coulombehuntingtonjasmin anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT bertomeuthierry anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT henrydanielle anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT huardcaroline anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT bonneileric anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT thibaultpierre anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT tyersmike anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT harringtonlea anovelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT benslimaneyahya novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT sanchezosunamaria novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT coulombehuntingtonjasmin novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT bertomeuthierry novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT henrydanielle novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT huardcaroline novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT bonneileric novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT thibaultpierre novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT tyersmike novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition
AT harringtonlea novelp53regulatorc16orf72tapr1buffersagainsttelomeraseinhibition